Transcriptional upregulation of c‐MYC by AXL confers epirubicin resistance in esophageal adenocarcin...
Transcriptional upregulation of c‐MYC by AXL confers epirubicin resistance in esophageal adenocarcinoma
About this item
Full title
Author / Creator
Publisher
United States: John Wiley & Sons, Inc
Journal title
Language
English
Formats
Publication information
Publisher
United States: John Wiley & Sons, Inc
Subjects
More information
Scope and Contents
Contents
AXL receptor tyrosine kinase is overexpressed in esophageal adenocarcinoma (EAC) and several other types of malignancies; hence, it may be a valuable therapeutic target. Herein, we investigated the role of AXL in regulating c‐MYC expression and resistance to the chemotherapeutic agent epirubicin in EAC. Using in vitro EAC cell models, we found that...
Alternative Titles
Full title
Transcriptional upregulation of c‐MYC by AXL confers epirubicin resistance in esophageal adenocarcinoma
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_0f5b74139a50496ba15e2ebcd8fe1267
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_0f5b74139a50496ba15e2ebcd8fe1267
Other Identifiers
ISSN
1574-7891
E-ISSN
1878-0261
DOI
10.1002/1878-0261.12395
